RANDI SILLER: Open Payments
NPI 1881918258 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$537 in 13 payments from 9 companies in 2025. Trend: 2023 $240 · 2024 $520 · 2025 $537
Food & beverage: $537
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $169 |
| Janssen Biotech, Inc. | 3 | $96 |
| PFIZER INC. | 2 | $64 |
| JAZZ PHARMACEUTICALS INC. | 1 | $60 |
| Merck Sharp & Dohme LLC | 1 | $34 |
| GlaxoSmithKline, LLC. | 1 | $32 |
| Incyte Corporation | 1 | $29 |
| SOBI, INC | 1 | $29 |
| Gamida Cell Inc. | 1 | $24 |
Products named: Xospata, DARZALEX, ELREXFIO, DEFITELIO, PREVYMIS, OJJAARA, Cresemba, NIKTIMVO.
Industry payments across TX — which companies pay providers there.
